We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+34.97%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$178M
AUM Growth
+$25.2M
Cap. Flow
-$21.5M
Cap. Flow %
-12.05%
Top 10 Hldgs %
99.49%
Holding
14
New
–
Increased
–
Reduced
2
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$5.01M
3
REPL icon
Replimune Group
REPL
+$955K
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$510K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$69.7M 39.05%
3,001,319
-48,868
-2% -$955K
NUVB icon
2
Nuvation Bio
NUVB
$2.24B
$27.1M 15.2%
15,072,340
– –
ALPN
3
DELISTED
Alpine Immune Sciences Inc
ALPN
$20.9M 11.69%
2,029,580
– –
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$17.8M 9.95%
309,846
-287,877
-48% -$15M
IMA
5
ImageneBio Inc
IMA
$63.1M
$14.8M 8.27%
187,427
– –
THRX
6
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$6.64M 3.72%
711,479
– –
KRON
7
DELISTED
Kronos Bio
KRON
$6.57M 3.68%
3,818,283
– –
SANA icon
8
Sana Biotechnology
SANA
$885M
$5.03M 2.82%
843,750
– –
SPRB
9
Spruce Biosciences
SPRB
$119M
$4.65M 2.6%
28,814
– –
IMUX icon
10
Immunic
IMUX
$182M
$4.49M 2.51%
178,816
– –
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$792K 0.44%
251,270
– –
SNTI icon
12
Senti Biosciences Holdings
SNTI
$12.6M
$123K 0.07%
19,579
– –
PRTK
13
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-1,971,241
Closed -$5.01M
JNCE
14
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-275,513
Closed -$510K

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q2 2023 Portfolio in Review

As of Q2 2023, Omega Fund Management held 14 positions worth $178M, up 16% from $153M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Omega Fund Management withdrew a net $21.5M in Q2 2023, closing 2 positions and reducing 2 holdings. Its most notable exit was Paratek Pharmaceuticals, Inc., an estimated $5.01M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Omega Fund Management's biggest Q2 2023 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $15M.
  • Omega Fund Management fully exited Paratek Pharmaceuticals, Inc. in Q2 2023, selling an estimated $5.01M.
  • Omega Fund Management's ten largest holdings make up 99% of its $178M portfolio in Q2 2023.
  • Omega Fund Management opened 0 new positions and closed 2 in Q2 2023.
  • Omega Fund Management's portfolio value rose 16% quarter-over-quarter to $178M.

Based on Omega Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.